


EIS Eligible.

Smart Matrix Limited seeks £6.5m to reach regulatory approval and potential exit

SmartMatrixLTD

www.smartmatrix.co.uk



Sector:
Medical Devices

Stage:
Pre-revenue

Location:
London

Roles available:
Not Hiring

Spun out of the highly respected medical research charity RAFT, Smart Matrix Limited (SML) was founded to commercialise a suite of regenerative medicine products based on a proprietary platform technology developed by scientists at the charity.

Smart Matrix®, the first application of the technology to be commercialised, designed to help the body to heal acute wounds, like those produced by skin cancer surgery, that would otherwise require the harvesting and placement of a skin graft.

Whilst a standard of care in the treatment of acute wounds, the healed result is frequently less flexible and stretchy than normal skin, leading to functional restrictions. Grafted wounds tend to heal with an appearance that is different to the surrounding skin. Together these factors can have a significant adverse impact on a patient's quality of life.


Results from a first-in-human clinical trial suggest that Smart Matrix® produces a healed result that closely matches the functional and appearance characteristics of normal skin, potentially bringing significant benefits to patients and healthcare providers alike.

Comprising a significant proportion of the acute surgical wound market, 3.3 million patients are diagnosed with non-melanoma skin cancer (NMSC) in the USA annually (source: www.skincancer.org). According to clinical key opinion leaders, 25% of patients undergoing surgery for non-facial NMSC will require a skin graft to heal their surgical wound, equating to an annual revenue opportunity in excess of \$2bn in the USA alone.

The management team is led by Andy Hill, a medical device industry veteran with experience of building early-stage businesses in Europe and the USA.

Scalable raw material supply and contract manufacturing capabilities are in place. The Company will start enrolling patients in the clinical trial in Q1 2018 and regulatory approval is expected in late 2020.

Having raised £5.4m to date, the company is raising a further £6.5m to conduct a pivotal clinical trial to secure regulatory approval in Europe and potential exit, most likely to a trade sale.



 **For more information, please contact:**
Andy Hill on hilla@smartmatrix.co.uk or call 07540 746784

The value of investments can go down as well as up, so you could get back less than or none of your invested capital. This opportunity may not be suitable or appropriate for your personal circumstances. The levels and basis of taxation may change and depends on your individual circumstances. The marketability of this type of investment is often restricted and you may have difficulty selling at any price. If you are in any doubt, you should consult a suitably qualified financial advisor.

This Financial Promotion is approved for the purposes of the Financial Services and Markets Act 2000 by Sturgeon Ventures LLP, which is authorised and regulated by the Financial Services Authority (FRN 452811). None of the underlying company's activities, finances or documentation have been reviewed or verified by Sturgeon Ventures LLP, nor has it conducted due diligence on any of its Principals or Directors. An investment into the underlying company is not covered by the Financial Services Compensation Scheme.